Literature DB >> 34202420

Deletion Mutants of Francisella Phagosomal Transporters FptA and FptF Are Highly Attenuated for Virulence and Are Protective Against Lethal Intranasal Francisella LVS Challenge in a Murine Model of Respiratory Tularemia.

Brandi E Hobbs1,2, Courtney A Matson2, Vasileios I Theofilou3, Tonya J Webb2,4, Rania H Younis3,4, Eileen M Barry1,2.   

Abstract

Francisella tularensis (Ft) is a Gram-negative, facultative intracellular bacterium that is a Tier 1 Select Agent of concern for biodefense for which there is no licensed vaccine. A subfamily of 9 Francisella phagosomal transporter (fpt) genes belonging to the Major Facilitator Superfamily of transporters was identified as critical to pathogenesis and potential targets for attenuation and vaccine development. We evaluated the attenuation and protective capacity of LVS derivatives with deletions of the fptA and fptF genes in the C57BL/6J mouse model of respiratory tularemia. LVSΔfptA and LVSΔfptF were highly attenuated with LD50 values of >20 times that of LVS when administered intranasally and conferred 100% protection against lethal challenge. Immune responses to the fpt mutant strains in mouse lungs on day 6 post-infection were substantially modified compared to LVS and were associated with reduced organ burdens and reduced pathology. The immune responses to LVSΔfptA and LVSΔfptF were characterized by decreased levels of IL-10 and IL-1β in the BALF versus LVS, and increased numbers of B cells, αβ and γδ T cells, NK cells, and DCs versus LVS. These results support a fundamental requirement for FptA and FptF in the pathogenesis of Ft and the modulation of the host immune response.

Entities:  

Keywords:  C57BL/6J mice; Francisella tularensis; Live Vaccine Strain (LVS); MFS transporter; attenuation; cytokines; flow cytometry; histopathology; live attenuated vaccine; organ burdens

Year:  2021        PMID: 34202420     DOI: 10.3390/pathogens10070799

Source DB:  PubMed          Journal:  Pathogens        ISSN: 2076-0817


  98 in total

1.  Safety, immunogenicity, and transmissibility in humans of CVD 1203, a live oral Shigella flexneri 2a vaccine candidate attenuated by deletions in aroA and virG.

Authors:  K L Kotloff; F Noriega; G A Losonsky; M B Sztein; S S Wasserman; J P Nataro; M M Levine
Journal:  Infect Immun       Date:  1996-11       Impact factor: 3.441

Review 2.  Tularemia as a biological weapon: medical and public health management.

Authors:  D T Dennis; T V Inglesby; D A Henderson; J G Bartlett; M S Ascher; E Eitzen; A D Fine; A M Friedlander; J Hauer; M Layton; S R Lillibridge; J E McDade; M T Osterholm; T O'Toole; G Parker; T M Perl; P K Russell; K Tonat
Journal:  JAMA       Date:  2001-06-06       Impact factor: 56.272

3.  Different host defences are required to protect mice from primary systemic vs pulmonary infection with the facultative intracellular bacterial pathogen, Francisella tularensis LVS.

Authors:  J Wayne Conlan; Rhonda KuoLee; Hua Shen; Ann Webb
Journal:  Microb Pathog       Date:  2002-03       Impact factor: 3.738

Review 4.  Tularaemia: bioterrorism defence renews interest in Francisella tularensis.

Authors:  Petra C F Oyston; Anders Sjostedt; Richard W Titball
Journal:  Nat Rev Microbiol       Date:  2004-12       Impact factor: 60.633

5.  Tracking the tissue distribution of marker dye following intranasal delivery in mice and chinchillas: a multifactorial analysis of parameters affecting nasal retention.

Authors:  Anju Visweswaraiah; Laura A Novotny; Erik J Hjemdahl-Monsen; Lauren O Bakaletz; Yasmin Thanavala
Journal:  Vaccine       Date:  2002-08-19       Impact factor: 3.641

6.  Experimental tularemia in mice challenged by aerosol or intradermally with virulent strains of Francisella tularensis: bacteriologic and histopathologic studies.

Authors:  J Wayne Conlan; Wangxue Chen; Hua Shen; Ann Webb; Rhonda KuoLee
Journal:  Microb Pathog       Date:  2003-05       Impact factor: 3.738

7.  Infected-host-cell repertoire and cellular response in the lung following inhalation of Francisella tularensis Schu S4, LVS, or U112.

Authors:  Joshua D Hall; Matthew D Woolard; Bronwyn M Gunn; Robin R Craven; Sharon Taft-Benz; Jeffrey A Frelinger; Thomas H Kawula
Journal:  Infect Immun       Date:  2008-10-13       Impact factor: 3.441

Review 8.  Live attenuated tularemia vaccines: recent developments and future goals.

Authors:  Mark E Marohn; Eileen M Barry
Journal:  Vaccine       Date:  2013-06-10       Impact factor: 3.641

9.  Identification of transposon insertion mutants of Francisella tularensis tularensis strain Schu S4 deficient in intracellular replication in the hepatic cell line HepG2.

Authors:  Aiping Qin; Barbara J Mann
Journal:  BMC Microbiol       Date:  2006-07-31       Impact factor: 3.605

10.  A Francisella tularensis Schu S4 purine auxotroph is highly attenuated in mice but offers limited protection against homologous intranasal challenge.

Authors:  Roger D Pechous; Travis R McCarthy; Nrusingh P Mohapatra; Shilpa Soni; Renee M Penoske; Nita H Salzman; Dara W Frank; John S Gunn; Thomas C Zahrt
Journal:  PLoS One       Date:  2008-06-25       Impact factor: 3.240

View more
  1 in total

1.  Alginate microencapsulation of an attenuated O-antigen mutant of Francisella tularensis LVS as a model for a vaccine delivery vehicle.

Authors:  Kelly C Freudenberger Catanzaro; Kevin K Lahmers; Irving C Allen; Thomas J Inzana
Journal:  PLoS One       Date:  2022-03-11       Impact factor: 3.240

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.